文献速递瓣膜病与结构性心脏病冠心病

LPA基因变异、心脏手术患者钙化性主动脉瓣狭窄及主动脉瓣微钙化的家族风险

Genetic Variation in LPA, Calcific Aortic Valve Stenosis in Patients Undergoing Cardiac Surgery, and Familial Risk of Aortic Valve Microcalcification.
PubMed 文献 · JAMA Cardiol · 2019-01-01

本研究基于多个遗传关联研究(含QUEBEC-CAVS队列、UK Biobank等)探讨LPA变异与钙化性主动脉瓣狭窄(CAVS)的关联,并比较合并与不合并冠心病(CAD)患者。结果显示,Lp(a)升高的遗传风险评分每增加1个标准差,CAVS风险在CAD患者(OR 1.30)与无CAD者(OR 1.33)中均升高;CAVS且高Lp(a)患者的一级亲属主动脉瓣微钙化比例更高(49% vs 13%)。

要点

  • Lp(a)遗传风险评分升高与CAVS风险独立于CAD存在。
  • CAVS合并高Lp(a)患者的一级亲属主动脉瓣微钙化比例显著高于对照。
  • 研究支持在CAVS中开展Lp(a)级联筛查的进一步研究。

核心结论

  • 遗传性升高的Lp(a)水平与CAVS独立于CAD存在关联。
  • 研究结果支持进一步探索Lp(a)级联筛查在CAVS中的潜在价值。

研究设计与样本

  • 遗传关联研究,纳入QUEBEC-CAVS队列心脏手术患者1009例及对照1017例。
  • 家族研究纳入17例CAVS且高Lp(a)(≥60 mg/dL)患者的一级亲属33例及Lp(a)正常(<60 mg/dL)对照23例。

关键数值与推荐

  • 遗传风险评分基于3个常见Lp(a)升高变异构建。
  • 高Lp(a)定义:≥60 mg/dL;正常Lp(a)定义:<60 mg/dL。
  • 主动脉瓣微钙化定义:氟18标记氟化钠PET/CT测得组织/本底比值≥1.25。

临床怎么用

  • 对CAVS患者可考虑评估Lp(a)水平以识别家族聚集风险。
  • Lp(a)升高与CAVS的关联独立于CAD,合并CAD不影响风险评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Genetic variants at the LPA locus are associated with both calcific aortic valve stenosis (CAVS) and coronary artery disease (CAD). Whether these variants are associated with CAVS in patients with CAD vs those without CAD is unknown. OBJECTIVE: To study the associations of LPA variants with CAVS in a cohort of patients undergoing heart surgery and LPA with CAVS in patients with CAD vs those without CAD and to determine whether first-degree relatives of patients with CAVS and high lipoprotein(a) (Lp[a]) levels showed evidence of aortic valve microcalcification. DESIGN, SETTING, AND PARTICIPANTS: This genetic association study included patients undergoing cardiac surgery from the Genome-Wide Association Study on Calcific Aortic Valve Stenosis in Quebec (QUEBEC-CAVS) study and patients with CAD, patients without CAD, and control participants from 6 genetic association studies: the UK Biobank, the European Prospective Investigation of Cancer (EPIC)-Norfolk, and Genetic Epidemiology Research on Aging (GERA) studies and 3 French cohorts. In addition, a family study included first-degree relatives of patients with CAVS. Data were collected from January 1993 to September 2018, and analysis was completed from September 2017 to September 2018. EXPOSURES: Case-control studies. MAIN OUTCOMES AND MEASURES: Presence of CAVS according to a weighted genetic risk score based on 3 common Lp(a)-raising variants and aortic valve microcalcification, defined as the mean tissue to background ratio of 1.25 or more, measured by fluorine 18-labeled sodium fluoride positron emission tomography/computed tomography. RESULTS: This study included 1009 individuals undergoing cardiac surgery and 1017 control participants in the QUEBEC-CAVS cohort; 3258 individuals with CAVS and CAD, 41 100 controls with CAD, 2069 individuals with CAVS without CAD, and 380 075 control participants without CAD in the UK Biobank, EPIC-Norfolk, and GERA studies and 3 French cohorts combined; and 33 first-degree relatives of 17 patients with CAVS and high Lp(a) levels (≥60 mg/dL) and 23 control participants with normal Lp(a) levels (<60 mg/dL). In the QUEBEC-CAVS study, each SD increase of the genetic risk score was associated with a higher risk of CAVS (odds ratio [OR], 1.35 [95% CI, 1.10-1.66]; P = .003). Each SD increase of the genetic risk score was associated with a higher risk of CAVS in patients with CAD (OR, 1.30 [95% CI, 1.20-1.42]; P < .001) and without CAD (OR, 1.33 [95% CI, 1.14-1.55]; P < .001). The percentage of individuals with a tissue to background ratio of 1.25 or more or CAVS was higher in first-degree relatives of patients with CAVS and high Lp(a) (16 of 33 [49%]) than control participants (3 of 23 [13%]; P = .006). CONCLUSIONS AND RELEVANCE: In this study, a genetically elevated Lp(a) level was associated with CAVS independently of the presence of CAD. These findings support further research on the potential usefulness of Lp(a) cascade screening in CAVS.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Perrot N, Thériault S, Dina C, et al. Genetic Variation in LPA, Calcific Aortic Valve Stenosis in Patients Undergoing Cardiac Surgery, and Familial Risk of Aortic Valve Microcalcification. JAMA Cardiol. 2019. PMID: 31141105. doi:10.1001/jamacardio.2019.1581

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。